Answers are grounded in this paper and cite their sources.
Retrospective cohort study shows improved survival in male breast cancer with neoadjuvant chemotherapy, highlighting specific patient benefits.
The survival benefit of neoadjuvant chemotherapy (Neo-CT) among male breast carcinoma (MaBC) remains unclear, and the specific population that can benefit from Neo-CT is also not yet defined. We utilized the data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database and employed Kaplan-Meier analysis; Cox proportional hazards model and binary variable Logistic regression were performed to evaluate the effect of Neo-CT on the therapeutic response and prognosis of MaBC patients. Among the 4171 MaBC subjects included, 194 (4.7%) patients received Neo-CT only (Neo-CT only group), 246 (5.9%) cases received adjuvant chemotherapy and Neo-CT (CT + Neo-CT group); the remaining 3731 (89.5%) cases received postoperative chemotherapy only (CT-only group). Totally, 20 (12.12%) participants achieved pathological complete response (pCR). And patients who achieved a pCR (pCR subgroup) had improved 5-year and 10-year overall survival (OS) (100.0% vs. 79.70% vs. 73.81%, 100.0% vs. 59.12% vs. 28.82%, respectively) and breast cancer-specific survival (BCSS) (86.30% vs. 91.49%, 69.04% vs. 83.32%, respectively) in comparison with those in the Non-pCR subgroup. Further binary Logistic regression analysis showed that the achievement of pCR might be related to stage I-II (p = 0.007) and hormone receptor (HR) negative (p = 0.010) disease, and the pCR rate of stage I-II and HR- MaBC patients was 66.67%.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: